Oxazepam

Summary

Oxazepam (CHEMBL568) is an approved small-molecule anxiolytic drug (ATC N05BA04); indicated across 8 conditions including anxiety and psychiatric disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05BA04
• Indications: 8 conditions
• Clinical trials: 6
• Chemistry: 286.71 Da · C15H11ClN2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL568
Name	Oxazepam
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4616
ChEBI	CHEBI:7823
ATC	N05BA04
Molecular formula	C15H11ClN2O2
Molecular weight	286.71
InChIKey	ADIMAYPTOBDMTL-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O

IUPAC name: 7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one

ChEBI definition: A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5.

Pharmacological roles (ChEBI): anxiolytic drug.

Other ChEBI roles (chemical / environmental): xenobiotic, environmental contaminant.

Also known as: J3.308A, Lederpam, NSC-169448, Oxazepam, Oxazepam civ, Oxozepam, Serax, Serenid fte, Temazepam impurity, oxazepam-, WY-3498, Zaxopam

Parent form; salt/anhydrous children: CHEMBL3251468

Patent coverage: 6,543 distinct patent families (26,207 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 26,190 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Prelamin-A/C, Menin/Histone-lysine N-methyltransferase MLL, Albumin, Gamma-aminobutyric acid receptor subunit alpha-1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P62813	7.52	AC50	30	nM	CHEMBL_ACT_25130755
LMNA	6.35	Potency	446.7	nM	CHEMBL_ACT_3630525

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

8 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
anxiety	4	MONDO:0011918	EFO:0005230
anxiety disorder	4	MONDO:0005618	EFO:0006788
psychiatric disorder	4	MONDO:0002025	HP:0000713
dementia	3	MONDO:0001627	HP:0000726
depressive disorder	3	MONDO:0002050	MONDO:0002050
HIV infectious disease	1	MONDO:0005109	EFO:0000764
nicotine dependence	1	MONDO:0008575	EFO:0003768

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE1	3
PHASE4	1
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02090504	PHASE4	COMPLETED	Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome
NCT02374567	PHASE3	TERMINATED	Pharmacovigilance in Gerontopsychiatric Patients
NCT00000661	PHASE1	COMPLETED	The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient
NCT02273453	PHASE1	COMPLETED	Study to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets
NCT02406066	PHASE1	COMPLETED	Single and Multiple Rising Dose Study of Safety and PK of Metyrapone/Oxazepam Combination (EMB-001)
NCT00567814	Not specified	COMPLETED	A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 2 clinical and 8 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).